Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies

Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1), have shown good resul...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Med
Asıl Yazarlar: Dika, Emi, Lambertini, Martina, Gouveia, Bruna, Mussi, Martina, Marcelli, Emanuela, Campione, Elena, Gurioli, Carlotta, Melotti, Barbara, Alessandrini, Aurora, Ribero, Simone
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2021
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8003791/
https://ncbi.nlm.nih.gov/pubmed/33808846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10061283
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller